Anixa Biosciences ANIX
NASDAQ ANIX
$2.95 +0.18 (+6.50%)
At close: Oct 2, 2026 · 4:00 PM EDT

Anixa Biosciences (ANIX) Asset Writedowns and Impairment (2019)

Updated

Anixa Biosciences' Asset Writedowns and Impairment came in at $418,750 for FY2019 (year ended Oct 31, 2019), down 28.2% from $582,979 in FY2018.

Analysis

Anixa Biosciences (ANIX) Asset Writedowns and Impairment (2019) Analysis & Trends

  • Per Business Quant, earlier fiscal years put Asset Writedowns and Impairment at $582,979 in FY2018.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Anixa Biosciences 102.02 Mn 100.75 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jan 31, 2019 418,750.00
API Access

Anixa Biosciences Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=ANIX&period=max&api_key=YOUR_API_KEY